Tag Archives: cell-based cancer immunotherapy

October, 2016

3 October
Bluebird Bio and Medigene Enter $1 Billion+ Cancer Immunotherapy Deal

MARTINSRIED/MUNICH & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, and bluebird bio, Inc. (Nasdaq: BLUE), USA, today announced the signing of a strategic research and development collaboration and licensing agreement encompassing T cell receptor (TCR) immunotherapies against four targets. “We are delighted to collaborate with bluebird bio, a …
Share

27 March
RXi and MirImmune Enter Licensing Deal for RXi’s Technology for Development of Cell-Based Cancer Immunotherapies

RXi Pharmaceuticals and privately-held MirImmune have entered into a license agreement to use RXi’s novel and proprietary technology for development of cell-based cancer drugs. The companies announced that they have entered into an exclusive license agreement to RXi’s sd-rxRNA technology for use in developing innovative cell-based cancer immunotherapies. The collaboration …
Share